These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 36460257)
1. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. Kreher MA; Noland MMB; Konda S; Longo MI; Valdes-Rodriguez R J Am Acad Dermatol; 2023 Mar; 88(3):521-530. PubMed ID: 36460257 [TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients. Gluck M; Hodak E; Davidovici B Dermatol Ther; 2022 Aug; 35(8):e15649. PubMed ID: 35716099 [TBL] [Abstract][Full Text] [Related]
3. Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors. Kreher MA; Konda S; Noland MMB; Longo MI; Valdes-Rodriguez R J Am Acad Dermatol; 2023 Mar; 88(3):534-542. PubMed ID: 36460256 [TBL] [Abstract][Full Text] [Related]
4. Immunity against Non-Melanoma Skin Cancer and the Effect of Immunosuppressive Medication on Non-Melanoma Skin Cancer Risk in Solid Organ Transplant Recipients. Bakker D; Bakker WJ; Bekkenk MW; Luiten RM Cells; 2023 Oct; 12(20):. PubMed ID: 37887285 [TBL] [Abstract][Full Text] [Related]
5. Non-melanoma skin cancer is reduced after switch of immunosuppression to mTOR-inhibitors in organ transplant recipients. Alter M; Satzger I; Schrem H; Kaltenborn A; Kapp A; Gutzmer R J Dtsch Dermatol Ges; 2014 Jun; 12(6):480-8. PubMed ID: 24813579 [TBL] [Abstract][Full Text] [Related]
6. Skin cancer in organ transplant recipients: more than the immune system. Wheless L; Jacks S; Mooneyham Potter KA; Leach BC; Cook J J Am Acad Dermatol; 2014 Aug; 71(2):359-65. PubMed ID: 24725477 [TBL] [Abstract][Full Text] [Related]
7. Cancer and mTOR Inhibitors in Transplant Recipients. de Fijter JW Transplantation; 2017 Jan; 101(1):45-55. PubMed ID: 27547865 [TBL] [Abstract][Full Text] [Related]
8. Does the nature of residual immune function explain the differential risk of non-melanoma skin cancer development in immunosuppressed organ transplant recipients? Jung JW; Overgaard NH; Burke MT; Isbel N; Frazer IH; Simpson F; Wells JW Int J Cancer; 2016 Jan; 138(2):281-92. PubMed ID: 25612559 [TBL] [Abstract][Full Text] [Related]
9. Interventions to Prevent Nonmelanoma Skin Cancers in Recipients of a Solid Organ Transplant: Systematic Review of Randomized Controlled Trials. Chung EYM; Palmer SC; Strippoli GFM Transplantation; 2019 Jun; 103(6):1206-1215. PubMed ID: 31246934 [TBL] [Abstract][Full Text] [Related]
10. Calcineurin inhibitor-free immunosuppression in pediatric renal transplantation: a viable option? Höcker B; Tönshoff B Paediatr Drugs; 2011 Feb; 13(1):49-69. PubMed ID: 21162600 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management. Ferrándiz-Pulido C; Leiter U; Harwood C; Proby CM; Guthoff M; Scheel CH; Westhoff TH; Bouwes Bavinck JN; Meyer T; Nägeli MC; Del Marmol V; Lebbé C; Geusau A Transplantation; 2023 Jul; 107(7):1452-1462. PubMed ID: 36706163 [TBL] [Abstract][Full Text] [Related]
12. Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist. Berman H; Shimshak S; Reimer D; Brigham T; Hedges MS; Degesys C; Tolaymat L Mayo Clin Proc; 2022 Dec; 97(12):2355-2368. PubMed ID: 36334939 [TBL] [Abstract][Full Text] [Related]
13. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Connolly K; Manders P; Earls P; Epstein RJ Cancer Treat Rev; 2014 Mar; 40(2):205-14. PubMed ID: 24051018 [TBL] [Abstract][Full Text] [Related]
14. Overview on non-melanoma skin cancers in solid organ transplant recipients. Forchetti G; Suppa M; Del Marmol V G Ital Dermatol Venereol; 2014 Aug; 149(4):383-7. PubMed ID: 25068224 [TBL] [Abstract][Full Text] [Related]
15. The impact of switching to mTOR inhibitor-based immunosuppression on long-term non-melanoma skin cancer incidence and renal function in kidney and liver transplant recipients. Murray SL; Daly FE; O'Kelly P; O'Leary E; Deady S; O'Neill JP; Dudley A; Rutledge NR; McCormick A; Houlihan DD; Williams Y; Morris PG; Ni Raghallaigh S; Moloney FJ; Sexton DJ; Conlon PJ Ren Fail; 2020 Nov; 42(1):607-612. PubMed ID: 32605413 [No Abstract] [Full Text] [Related]
16. Nonmelanoma Skin Cancers After Kidney Transplant: Our 15 Years of Experience With Mammalian Target of Rapamycin Inhibitors. Okut G; Alp A; Tatar E; Simsek C; Tugmen C; Uslu A Exp Clin Transplant; 2017 Feb; 15(Suppl 1):236-239. PubMed ID: 28260475 [TBL] [Abstract][Full Text] [Related]
17. [Immunosuppressive drugs and the development of skin cancer after organ transplantation]. Gjersvik P; Helsing P; Holdaas H; Bergan S Tidsskr Nor Laegeforen; 2012 Oct; 132(18):2064-8. PubMed ID: 23038197 [TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. Gutierrez-Dalmau A; Campistol JM Drugs; 2007; 67(8):1167-98. PubMed ID: 17521218 [TBL] [Abstract][Full Text] [Related]
19. Cutaneous squamous cell carcinomas in solid organ transplant recipients: emerging strategies for surveillance, staging, and treatment. Kim C; Cheng J; Colegio OR Semin Oncol; 2016 Jun; 43(3):390-4. PubMed ID: 27178693 [TBL] [Abstract][Full Text] [Related]
20. Skin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repair. Kuschal C; Thoms KM; Schubert S; Schäfer A; Boeckmann L; Schön MP; Emmert S Exp Dermatol; 2012 Jan; 21(1):2-6. PubMed ID: 22151386 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]